Neurol. praxi. 2021;22(4):300-302 | DOI: 10.36290/neu.2021.048
Shorter infusion of ocrelizumab in the treatment of multiple sclerosis
- Neurologická klinika, LF UK a FN Plzeň
Patients with multiple sclerosis can nowadays be treated with the humanized monoclonal antibody ocrelizumab. This drug has so far been administered parenterally intravenously at an interval of 3,5 hours. As we know from other fields of medicine, reducing the infusion time can minimise the burden of treatment on patients and reduce the length of stay in the infusion room without compromising patient safety, which is especially important in the light of the current COVID-19 pandemic. The ENSEMBLE PLUS study investigated the safety of ocrelizumab administration when the infusion time was reduced to 2 hours. This article reports the results of this study.
Keywords: multiple sclerosis, ocrelizumab, shorter, infusion, infusion-related reactions.
Accepted: July 10, 2021; Prepublished online: July 10, 2021; Published: September 1, 2021 Show citation
References
- European Medicines Agency. Ocrevus [Summary of Product Characteristics] (2020). https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf. Accessed 24 July, 2020.
- Hartung HP; ENSEMBLE Steering Committee members and study investigators. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e807.
Go to PubMed... - Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, RammohanKW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Mastermann D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 2017; 376(3): 221-234.
Go to original source... Go to PubMed... - Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 2017; 376(3): 209-220. Go to original source... Go to PubMed...